Find policies, billing codes, payers, states, and providers

Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview

DRG 883 addresses inpatient hospitalizations for disorders of personality and impulse control, encompassing diagnoses that affect behavior regulation and social functioning and may require crisis or stabilization care. Accurate assignment of this Diagnosis-Related Group matters for inpatient reimbursement because Centers for Medicare & Medicaid Services payment hinges on the coded clinical complexity, documented severity, and presence of complications or comorbidities.

Customize your policy alerts

Sign up for Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 883 Overview

DRG 883 covers inpatient admissions primarily for disorders of personality and impulse control, including pervasive patterns of behavior that impair social and occupational functioning and acute presentations requiring stabilization. This Diagnosis-Related Group captures psychiatric interventions, observation, and resource use specific to personality and impulse control pathology during a hospital stay. It matters for Medicare payment because the Diagnosis-Related Group determines base reimbursement tied to documented diagnoses, length of stay, and any documented complications or comorbidities that affect resource utilization. Proper assignment of principal and secondary diagnoses influences payment under Centers for Medicare & Medicaid Services rules.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview

Customize your policy alerts

Sign up for Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 883 Overview

National Payment Rates

Across commercial payers the DRG rates range from as low as $370 (BCBS minimum) up to $52K (Cigna maximum), with mean payer payments spanning roughly $6K to $27K. The widest spread between payer minimums and maximums appears in the Cigna–Aetna–Cigna group, showing significant variability across commercial contracts; see the table and chart below for payer-level detail. These benchmarks highlight meaningful dispersion across Anthem, Aetna, BCBS, and Cigna.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($16.3k), average submitted covered charges ($56.6k), average Medicare payment ($13.1k), and total discharges (704).

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$16K	$57K	$13K	700

Patient Population

This DRG’s patient population is mixed but leans toward working-age adults under private/commercial coverage rather than exclusively Medicare-age beneficiaries. Medicare discharges are present (704 total in the CMS dataset) indicating a meaningful Medicare share, but commercial payers (Anthem, Aetna, BCBS, Cigna) also represent substantial utilization, reflecting a blend of payers across age groups.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

For DRG 883 payer-specific rates in Alaska span from $2.5K up to $54K across the included payers, reflecting substantial variability by insurer. Cigna posts the highest mean ($36K) and maximum ($54K), while Anthem and Blue Cross Blue Shield show the lowest reported minimums ($2.5K) and lower central tendencies (median $19K). These Alaska benchmarks deviate from national averages by exhibiting considerably higher top-end payments, as shown in the table and chart below.

Key Insights for Alaska

Highest payer: Cigna (max $54K, mean $36K, median $31K) represents the top regional rates; lowest payer: Anthem/Blue Cross Blue Shield (both share identical benchmarks with min $2.5K, mean $22K, median $19K).
Alaska’s payer range is wide ($2.5K to $54K) and the state mean levels (Cigna mean $36K; Anthem/BCBS mean $22K) sit well above typical national medians for this DRG, indicating materially higher reimbursement at the upper end.

Clinical Trials

Acute inpatient behavioral intervention trials: Studies testing time-limited, structured behavioral or psychotherapeutic interventions delivered during hospitalization for patients admitted with severe personality or impulse-control crises (for example, acute self-harm, suicidal ideation, or aggressive outbursts). These trials enroll adults with high-risk presentations requiring inpatient stabilization to assess short-term reduction in dangerous behaviors, need for restraint or seclusion, and safe disposition at discharge. Results are relevant to providers for optimizing in-hospital protocols and to payers because effective acute interventions can shorten length of stay and reduce use of high-intensity resources.
Comparative effectiveness studies of outpatient follow-up models after discharge: Research comparing different post-discharge care pathways such as intensive outpatient psychotherapy, community-based case management, or stepped-care coordination for patients discharged after inpatient stabilization for personality disorders or impulse-control disorders. These studies focus on real-world adult and sometimes adolescent populations at high risk for readmission, emergency visits, or recurrent self-harm, measuring outcomes like readmission rates, adherence to follow-up, and functional status. Findings inform clinicians and payers about which care transitions and service mixes best prevent costly readmissions and improve continuity of care.
Pragmatic trials of adjunctive therapies and service delivery in comorbid populations: Trials evaluating the addition of adjunctive interventions (for example, brief dialectical-behavior skills modules delivered by generalist staff, mobile health symptom monitoring, or family-involvement programs) in patients with personality or impulse-control disorders complicated by comorbid substance use, mood disorders, or medical conditions. These studies enroll heterogeneous inpatient and recently discharged cohorts to assess real-world effectiveness on impulse-related outcomes, treatment engagement, and downstream service utilization over months. The research matters to providers and payers because comorbidity drives complexity and costs; pragmatic evidence helps allocate resources toward scalable interventions that reduce long-term utilization and improve management across care settings.

O.R. Procedures with Principal Diagnosis of Mental Illness: Inpatient Reimbursement Overview

880-ACUTE-ADJUSTMENT-REACTION-AND-PSYCHOSOCIAL-DYSFUNCTION

Acute Adjustment Reaction and Psychosocial Dysfunction: Inpatient Reimbursement Overview

881-DEPRESSIVE-NEUROSES

Depressive Neuroses: Inpatient Reimbursement Overview

882-NEUROSES-EXCEPT-DEPRESSIVE

Neuroses Except Depressive: Inpatient Reimbursement Overview

884-ORGANIC-DISTURBANCES-AND-INTELLECTUAL-DISABILITY

Organic Disturbances and Intellectual Disability: Inpatient Reimbursement Overview

885-PSYCHOSES

Psychoses: Inpatient Reimbursement Overview

886-BEHAVIORAL-AND-DEVELOPMENTAL-DISORDERS

Behavioral and Developmental Disorders: Inpatient Reimbursement Overview

887-OTHER-MENTAL-DISORDER-DIAGNOSES

Other Mental Disorder Diagnoses: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

National Payment Rates

Mean Rates by Payer — National — DRG 883

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$16K	$57K	$13K	700

Patient Population

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 883

Key Insights for Alaska

Highest payer: Cigna (max $54K, mean $36K, median $31K) represents the top regional rates; lowest payer: Anthem/Blue Cross Blue Shield (both share identical benchmarks with min $2.5K, mean $22K, median $19K).
Alaska’s payer range is wide ($2.5K to $54K) and the state mean levels (Cigna mean $36K; Anthem/BCBS mean $22K) sit well above typical national medians for this DRG, indicating materially higher reimbursement at the upper end.

Clinical Trials

Acute inpatient behavioral intervention trials: Studies testing time-limited, structured behavioral or psychotherapeutic interventions delivered during hospitalization for patients admitted with severe personality or impulse-control crises (for example, acute self-harm, suicidal ideation, or aggressive outbursts). These trials enroll adults with high-risk presentations requiring inpatient stabilization to assess short-term reduction in dangerous behaviors, need for restraint or seclusion, and safe disposition at discharge. Results are relevant to providers for optimizing in-hospital protocols and to payers because effective acute interventions can shorten length of stay and reduce use of high-intensity resources.
Comparative effectiveness studies of outpatient follow-up models after discharge: Research comparing different post-discharge care pathways such as intensive outpatient psychotherapy, community-based case management, or stepped-care coordination for patients discharged after inpatient stabilization for personality disorders or impulse-control disorders. These studies focus on real-world adult and sometimes adolescent populations at high risk for readmission, emergency visits, or recurrent self-harm, measuring outcomes like readmission rates, adherence to follow-up, and functional status. Findings inform clinicians and payers about which care transitions and service mixes best prevent costly readmissions and improve continuity of care.
Pragmatic trials of adjunctive therapies and service delivery in comorbid populations: Trials evaluating the addition of adjunctive interventions (for example, brief dialectical-behavior skills modules delivered by generalist staff, mobile health symptom monitoring, or family-involvement programs) in patients with personality or impulse-control disorders complicated by comorbid substance use, mood disorders, or medical conditions. These studies enroll heterogeneous inpatient and recently discharged cohorts to assess real-world effectiveness on impulse-related outcomes, treatment engagement, and downstream service utilization over months. The research matters to providers and payers because comorbidity drives complexity and costs; pragmatic evidence helps allocate resources toward scalable interventions that reduce long-term utilization and improve management across care settings.

O.R. Procedures with Principal Diagnosis of Mental Illness: Inpatient Reimbursement Overview

880-ACUTE-ADJUSTMENT-REACTION-AND-PSYCHOSOCIAL-DYSFUNCTION

Acute Adjustment Reaction and Psychosocial Dysfunction: Inpatient Reimbursement Overview

881-DEPRESSIVE-NEUROSES

Depressive Neuroses: Inpatient Reimbursement Overview

882-NEUROSES-EXCEPT-DEPRESSIVE

Neuroses Except Depressive: Inpatient Reimbursement Overview

884-ORGANIC-DISTURBANCES-AND-INTELLECTUAL-DISABILITY

Organic Disturbances and Intellectual Disability: Inpatient Reimbursement Overview

885-PSYCHOSES

Psychoses: Inpatient Reimbursement Overview

886-BEHAVIORAL-AND-DEVELOPMENTAL-DISORDERS

Behavioral and Developmental Disorders: Inpatient Reimbursement Overview

887-OTHER-MENTAL-DISORDER-DIAGNOSES

Other Mental Disorder Diagnoses: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview

Sign up for Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview policy alerts

DRG 883 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview

Sign up for Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview policy alerts

DRG 883 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References